A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
复制标题
西洛他唑（一种磷酸二酯酶抑制剂）及其在预防血管内治疗后冠状动脉和外周动脉再狭窄中的作用的综述。
DOI：
--
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
C. Kyriakides
中科院分区：
文献类型：
--
作者：
S. Dindyal;C. Kyriakides
在西方世界，全身性血管疾病是最大的死亡原因。治疗选择是通过药物治疗进行预防，或者通过手术旁路进行治疗。最近，微创血管内技术的使用和普及有所增加，特别是血管成形术和支架插入术。与传统手术相比，这些技术的短期结果已在许多研究中被证明是上级的，传统手术本身具有高死亡率和发病率。由于主要由内膜增生引起的血管再狭窄，血管内治疗的长期结果并不令人印象深刻。已经有大量的研究和治疗试验来发现再狭窄的解决方案，但迄今为止尚未取得成功。西洛他唑是一种磷酸二酯酶抑制剂，获准用于治疗间歇性跛行患者。最近的临床试验表明，西洛他唑也可以预防血管内治疗后冠状动脉再狭窄。最近外周血管支架重复了这些结果。本文就西洛他唑的药理作用、外周血管疾病、内膜增生导致血管再狭窄的机制等方面进行综述。我们还讨论了使用西洛他唑和其他目前专利的新的目标和治疗，预防冠状动脉和外周动脉疾病血管内治疗后再狭窄。
Systemic vascular disease is the greatest cause of mortality in the western world. Treatment options have been preventative with medical therapy or curative with surgical bypass. Recently, there has been an increase in the use and popularity of minimally invasive endovascular techniques, particularly angioplasty and stent insertions. The short-term results of these techniques have been demonstrated to be superior in a number of studies when compared with conventional surgery, which itself carries high mortality and morbidity. The long-term outcomes of endovascular treatments have not been as impressive, due to vascular restenosis caused mainly by intimal hyperplasia. There have been a large number of studies and therapeutic trials to discover a solution to restenosis, but to date success has not been reached. Cilostazol is a phosphodiesterase inhibitor licensed for treating patients suffering from intermittent claudication. Recent clinical trials have shown the effects of cilostazol in also preventing coronary artery restenosis post-endovascular treatments. These results have recently been repeated for peripheral vascular stents. This review discusses the pharmacology of cilostazol, peripheral vascular disease, mechanisms of intimal hyperplasia causing vascular restenosis. We also discuss the use of cilostazol and other current patents of novel targets and therapeutics, for preventing restenosis of both coronary and peripheral arterial disease following endovascular therapies.